vs
EyePoint, Inc.（EYPT）与帕可Bio（PACB）财务数据对比。点击上方公司名可切换其他公司
帕可Bio的季度营收约是EyePoint, Inc.的72.1倍（$44.6M vs $619.0K）。帕可Bio净利率更高（-90.4% vs -10922.3%，领先10831.9%）。帕可Bio同比增速更快（13.8% vs -94.7%）。帕可Bio自由现金流更多（$-19.9M vs $-66.0M）。过去两年帕可Bio的营收复合增速更高（7.3% vs -77.0%）
EyePoint制药公司总部位于马萨诸塞州沃特敦，是一家专注于将微机电系统（MEMS）与纳米技术应用于给药领域的专业医药企业，依托前沿交叉技术开发创新给药方案，聚焦眼科等领域的药物递送技术创新与产品开发。
太平洋生物科学（加利福尼亚）公司是2004年成立的美国生物技术企业，专注于研发生产基因测序相关设备，还可实现新型实时生物观测。公司拥有两大核心测序平台：基于零模波导特性的单分子实时测序平台（SMRT），以及采用天然核苷酸、无损伤掺入完成DNA结合与延伸的结合测序技术（SBB）平台。
EYPT vs PACB — 直观对比
营收规模更大
PACB
是对方的72.1倍
$619.0K
营收增速更快
PACB
高出108.5%
-94.7%
净利率更高
PACB
高出10831.9%
-10922.3%
自由现金流更多
PACB
多$46.1M
$-66.0M
两年增速更快
PACB
近两年复合增速
-77.0%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $619.0K | $44.6M |
| 净利润 | $-67.6M | $-40.4M |
| 毛利率 | — | 37.1% |
| 营业利润率 | -11364.3% | -92.3% |
| 净利率 | -10922.3% | -90.4% |
| 营收同比 | -94.7% | 13.8% |
| 净利润同比 | -63.3% | -1802.7% |
| 每股收益（稀释后） | $-0.82 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EYPTPACB
| Q4 25 | $619.0K | $44.6M | ||
| Q3 25 | $966.0K | $38.4M | ||
| Q2 25 | $5.3M | $39.8M | ||
| Q1 25 | $24.5M | $37.2M | ||
| Q4 24 | $11.6M | $39.2M | ||
| Q3 24 | $10.5M | $40.0M | ||
| Q2 24 | $9.5M | $36.0M | ||
| Q1 24 | $11.7M | $38.8M |
净利润EYPTPACB
| Q4 25 | $-67.6M | $-40.4M | ||
| Q3 25 | $-59.7M | $-38.0M | ||
| Q2 25 | $-59.4M | $-41.9M | ||
| Q1 25 | $-45.2M | $-426.1M | ||
| Q4 24 | $-41.4M | $2.4M | ||
| Q3 24 | $-29.4M | $-60.7M | ||
| Q2 24 | $-30.8M | $-173.3M | ||
| Q1 24 | $-29.3M | $-78.2M |
毛利率EYPTPACB
| Q4 25 | — | 37.1% | ||
| Q3 25 | — | 41.4% | ||
| Q2 25 | — | 36.9% | ||
| Q1 25 | — | -3.7% | ||
| Q4 24 | — | 25.6% | ||
| Q3 24 | 93.0% | 25.0% | ||
| Q2 24 | 85.2% | 16.5% | ||
| Q1 24 | 93.5% | 29.1% |
营业利润率EYPTPACB
| Q4 25 | -11364.3% | -92.3% | ||
| Q3 25 | -6420.8% | -101.1% | ||
| Q2 25 | -1166.8% | -112.8% | ||
| Q1 25 | -199.7% | -1154.5% | ||
| Q4 24 | -390.4% | -390.1% | ||
| Q3 24 | -311.2% | -160.3% | ||
| Q2 24 | -364.5% | -488.3% | ||
| Q1 24 | -285.2% | -209.6% |
净利率EYPTPACB
| Q4 25 | -10922.3% | -90.4% | ||
| Q3 25 | -6183.4% | -98.9% | ||
| Q2 25 | -1114.3% | -105.4% | ||
| Q1 25 | -184.8% | -1146.8% | ||
| Q4 24 | -357.3% | 6.0% | ||
| Q3 24 | -279.0% | -151.9% | ||
| Q2 24 | -325.3% | -481.3% | ||
| Q1 24 | -250.6% | -201.4% |
每股收益（稀释后）EYPTPACB
| Q4 25 | $-0.82 | $-0.11 | ||
| Q3 25 | $-0.85 | $-0.13 | ||
| Q2 25 | $-0.85 | $-0.14 | ||
| Q1 25 | $-0.65 | $-1.44 | ||
| Q4 24 | $-0.65 | $-0.44 | ||
| Q3 24 | $-0.54 | $-0.22 | ||
| Q2 24 | $-0.58 | $-0.64 | ||
| Q1 24 | $-0.55 | $-0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $306.1M | $279.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $306.1M | $5.3M |
| 总资产 | $364.0M | $784.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EYPTPACB
| Q4 25 | $306.1M | $279.5M | ||
| Q3 25 | $204.0M | $298.7M | ||
| Q2 25 | $255.7M | $314.7M | ||
| Q1 25 | $318.2M | $343.1M | ||
| Q4 24 | $370.9M | $389.9M | ||
| Q3 24 | $253.8M | $471.1M | ||
| Q2 24 | $280.2M | $509.8M | ||
| Q1 24 | $299.3M | $561.9M |
股东权益EYPTPACB
| Q4 25 | $306.1M | $5.3M | ||
| Q3 25 | $200.2M | $36.1M | ||
| Q2 25 | $246.0M | $61.5M | ||
| Q1 25 | $298.4M | $91.6M | ||
| Q4 24 | $336.5M | $506.6M | ||
| Q3 24 | $218.7M | $453.1M | ||
| Q2 24 | $228.3M | $492.7M | ||
| Q1 24 | $249.9M | $649.0M |
总资产EYPTPACB
| Q4 25 | $364.0M | $784.1M | ||
| Q3 25 | $251.7M | $803.2M | ||
| Q2 25 | $301.1M | $825.5M | ||
| Q1 25 | $362.6M | $860.8M | ||
| Q4 24 | $418.5M | $1.3B | ||
| Q3 24 | $300.9M | $1.5B | ||
| Q2 24 | $324.2M | $1.5B | ||
| Q1 24 | $329.2M | $1.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-65.0M | $-19.1M |
| 自由现金流经营现金流 - 资本支出 | $-66.0M | $-19.9M |
| 自由现金流率自由现金流/营收 | -10667.7% | -44.6% |
| 资本支出强度资本支出/营收 | 159.3% | 1.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-243.4M | $-114.1M |
8季度趋势，按日历期对齐
经营现金流EYPTPACB
| Q4 25 | $-65.0M | $-19.1M | ||
| Q3 25 | $-59.4M | $-18.7M | ||
| Q2 25 | $-62.6M | $-29.4M | ||
| Q1 25 | $-53.1M | $-44.1M | ||
| Q4 24 | $-35.8M | $-30.6M | ||
| Q3 24 | $-39.0M | $-45.5M | ||
| Q2 24 | $-20.2M | $-54.3M | ||
| Q1 24 | $-31.2M | $-75.7M |
自由现金流EYPTPACB
| Q4 25 | $-66.0M | $-19.9M | ||
| Q3 25 | $-60.2M | $-18.8M | ||
| Q2 25 | $-63.8M | $-29.9M | ||
| Q1 25 | $-53.4M | $-45.4M | ||
| Q4 24 | $-36.2M | $-32.3M | ||
| Q3 24 | $-40.6M | $-46.3M | ||
| Q2 24 | $-21.1M | $-55.7M | ||
| Q1 24 | $-32.4M | $-79.6M |
自由现金流率EYPTPACB
| Q4 25 | -10667.7% | -44.6% | ||
| Q3 25 | -6226.9% | -48.9% | ||
| Q2 25 | -1196.5% | -75.3% | ||
| Q1 25 | -218.4% | -122.3% | ||
| Q4 24 | -312.7% | -82.3% | ||
| Q3 24 | -385.8% | -115.7% | ||
| Q2 24 | -222.4% | -154.8% | ||
| Q1 24 | -277.0% | -205.0% |
资本支出强度EYPTPACB
| Q4 25 | 159.3% | 1.9% | ||
| Q3 25 | 82.6% | 0.2% | ||
| Q2 25 | 22.9% | 1.4% | ||
| Q1 25 | 1.1% | 3.7% | ||
| Q4 24 | 3.3% | 4.1% | ||
| Q3 24 | 15.0% | 2.0% | ||
| Q2 24 | 9.5% | 4.1% | ||
| Q1 24 | 10.2% | 10.0% |
现金转化率EYPTPACB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -12.93× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EYPT
暂无分部数据
PACB
| Products | $39.0M | 87% |
| Service And Other | $5.7M | 13% |
